(Q33750399)

29 July 2017

title

Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers (English)

1 reference

acute decompensated heart failure

29 July 2017

0 references

1 reference

Claes-Håkan Bergh

1

1 reference

29 July 2017

Bert Andersson

2

1 reference

29 July 2017

Ulf Dahlström

3

1 reference

29 July 2017

Kolbjorn Forfang

4

1 reference

29 July 2017

Matti Kivikko

5

1 reference

29 July 2017

Toni Sarapohja

6

1 reference

29 July 2017

Bengt Ullman

7

1 reference

29 July 2017

Gerhard Wikström

8

1 reference

29 July 2017

publication date

1 April 2010

1 reference

European Journal of Heart Failure

29 July 2017

published in

1 reference

29 July 2017

volume

12

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

404-410

1 reference

Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844760

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844760

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844760

HUMAN EXPERIMENTATION. CODE OF ETHICS OF THE WORLD MEDICAL ASSOCIATION. DECLARATION OF HELSINKI

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844760

Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844760

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844760

Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

14 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ032

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ032

Sustained hemodynamic effects of intravenous levosimendan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ032

A sharper Bonferroni procedure for multiple tests of significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ032

Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ032

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844760

Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators

30 October 2018

1 reference

12 December 2020

Tolerance to dobutamine after a 72 hour continuous infusion

1 reference

12 December 2020

Down-regulation of beta-adrenergic receptors on mononuclear leukocytes induced by dobutamine treatment in patients with congestive heart failure

1 reference

12 December 2020

Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan

1 reference

12 December 2020

Identifiers

DOI

10.1093/EURJHF/HFQ032

1 reference

29 July 2017

1 reference

29 July 2017

1 reference